| Objective:Discuss the preparation of dendritic cells(DC)and cytokineinduced killer cells(CIK)by in vitro isolation and induction culture of peripheral blood mononuclear cells(PBMC),and then mix CTL cells(Cytotoxic T lymphocyte,CTL)were prepared by culture,and the clinical efficacy of DC-CIK-CTL cell immunotherapy combined with chemotherapy intervention therapy for advanced cancer patients was treated.Methods: A retrospective analysis was performed on 55 hospitalized patients with advanced cancer in our hospital from 2014.04 to 2016.04.25 patients who received DC-CIK-CTL cell immunotherapy≤1 time and were combined with chemotherapy interventional were used as the control group,30 patients received DC-CIK-CTL cell immunotherapy≥2 times and combined chemotherapy intervention cases were listed as the observation group,regular review follow up after treatment,the last follow-up time is December 31,2019.The differences in objective response rate,disease control rate,progression-free survival,one-year survival rate,2-year survival rate,three-year survival rate,quality of life,tumor markers and other indicators of the two groups were compared.Results:The difference in progression-free survival between the two observation groups and the control group was statistically significant(P<0.05).The total objective response rate,ORR(Objective response rate)(CR+PR)was 10%,the observation group was 2% and 10% compared with the control group,the total disease control rate DCR(Disease control rate)(CR+PR+SD)was 67%,the observation group and the control group The comparison was: 32% and 10%,the difference was statistically significan t(P<0.05).The one-year survival rate,two-year survival rate and three-year survival rate of the observation group were 63.3%,40.0% and 13.3% respectively;the one-year survival rate,two-year survival rate and three-year survival rate of the control group were 32.0% and 20.0%,4.0% respectively;In survival analysis,the median survival time of the control group was 7 months(95%CI:5.610～8.390),and the median survival time of the observation group was 16 months(95%CI:10.632～21.368).In terms of quality of life,the total improvement rate reached 54%,the total improvement rate of the Kamofsky score of the observation group reached 36%,and the index of the control group was 70%.Through statistical analysis,it was confirmed that the difference between the two groups was statistically significant(P<0.05).In the observation group,the patient’s tumor markers changed significantly before and after treatment,and decreased to varying degrees,the tumor markers of the patients in the control group did not change significantly.Conclusion:1.DC-CIK-CTL cell therapy combined with chemotherapy intervention can improve the patient’s ORR,DCR and PFS,which is beneficial to the short-term and long-term efficacy of patients with advanced cancer.2.DC-CIK-CTL cell therapy combined with chemotherapy intervention can improve the quality of life of patients with advanced cancer and can reduce tumor markers to a certain extent.3.The side effects of DC-CIK-CTL cell therapy combined with chemotherapy intervention are within the acceptable range,and it is a selective treatment method for patients with advanced cancer. |
PDF Full Text Request